View by Specialty

Headline News

View more

Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer

May 01, 2024
3 min read
Save

Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer

Glecirasib may deliver &lsquo;efficacy and tolerability advantages&rsquo; for <i>KRAS</i>-mutant lung cancer

Nearly 50% of patients with pretreated, locally advanced non-small cell lung cancer harboring a KRAS G12C mutation responded to treatment with glecirasib, findings from a phase 2 study conducted in China showed.

View more Headline News
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails

Resources

View more

AI in Medicine

23007715_AIinMedicineRC_OG

Artificial intelligence is a rapidly evolving field. Learn how and why it is being applied in clinical practice in multiple medical specialties.

View resource

Biosimilars in the United States: Current Status and Future Implications

Residency to Retirement

Residency to Retirement

Insightful and innovative strategies to help physicians reduce taxes, protect assets, invest wisely and build wealth during all phases of their careers.

View resource
View more Resources
View more Meeting News
View meeting calendar

Podcasts

View more
Hematology/Oncology Oncology Overdrive
April 18, 2024
48 min listen

Learning Leadership with Jonathan D. Licht, MD

Hematology/Oncology Oncology Overdrive
April 04, 2024
32 min listen

Global GI Oncology with Aparna Parikh, MD

View more Podcasts

Blogs & Columns

View more
ASTCT Update is sponsored by American Society for Transplantation and Cellular Therapy, which is dedicated to the application and success of blood and marrow transplantation and related cellular therapies. The blog provides essential updates about research advances, health policy and clinical best practices to ensure optimal patient care. ASTCT provides additional practice resources on its website.



A column for advanced practice providers to share research advances, and discuss day-to-day practice and regulatory concerns.

View more Blogs & Columns